Free Trial

NeuroPace (NPCE) Competitors

NeuroPace logo
$10.39 +0.03 (+0.29%)
Closing price 04:00 PM Eastern
Extended Trading
$10.61 +0.22 (+2.12%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NPCE vs. BLFS, BBNX, SSII, KMTS, ESTA, MDXG, PLSE, INMD, IRMD, and EMBC

Should you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include BioLife Solutions (BLFS), Beta Bionics (BBNX), SS Innovations International (SSII), Kestra Medical Technologies (KMTS), Establishment Labs (ESTA), MiMedx Group (MDXG), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), and Embecta (EMBC). These companies are all part of the "medical equipment" industry.

NeuroPace vs. Its Competitors

BioLife Solutions (NASDAQ:BLFS) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioLife Solutions currently has a consensus price target of $31.29, indicating a potential upside of 26.41%. NeuroPace has a consensus price target of $16.60, indicating a potential upside of 59.77%. Given NeuroPace's higher probable upside, analysts plainly believe NeuroPace is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
NeuroPace
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

BioLife Solutions has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.

In the previous week, BioLife Solutions had 5 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for BioLife Solutions and 0 mentions for NeuroPace. BioLife Solutions' average media sentiment score of 1.42 beat NeuroPace's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media.

Company Overall Sentiment
BioLife Solutions Positive
NeuroPace Neutral

BioLife Solutions has higher revenue and earnings than NeuroPace. BioLife Solutions is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$82.25M14.41-$20.18M-$0.12-206.25
NeuroPace$79.91M4.30-$27.14M-$0.84-12.37

BioLife Solutions has a net margin of -5.39% compared to NeuroPace's net margin of -29.29%. BioLife Solutions' return on equity of 0.16% beat NeuroPace's return on equity.

Company Net Margins Return on Equity Return on Assets
BioLife Solutions-5.39% 0.16% 0.14%
NeuroPace -29.29%-168.61%-25.48%

Summary

BioLife Solutions beats NeuroPace on 13 of the 17 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NPCE vs. The Competition

MetricNeuroPaceMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$342.72M$6.83B$5.77B$10.52B
Dividend YieldN/A1.20%5.53%4.57%
P/E Ratio-12.3725.7676.4326.62
Price / Sales4.30199.41535.41119.74
Price / CashN/A21.9037.4661.85
Price / Book38.485.0513.616.45
Net Income-$27.14M$178.07M$3.29B$271.57M
7 Day Performance6.02%1.95%1.67%2.83%
1 Month Performance15.57%6.81%4.05%7.27%
1 Year Performance43.91%20.83%80.70%26.07%

NeuroPace Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NPCE
NeuroPace
2.6805 of 5 stars
$10.39
+0.3%
$16.60
+59.8%
+38.9%$342.72M$79.91M-12.37170
BLFS
BioLife Solutions
2.9855 of 5 stars
$25.80
+1.1%
$31.29
+21.3%
-1.9%$1.22B$82.25M-214.98440
BBNX
Beta Bionics
1.11 of 5 stars
$25.31
-4.2%
$22.56
-10.9%
N/A$1.15B$65.12M0.00294Analyst Forecast
SSII
SS Innovations International
N/A$5.40
-6.9%
N/AN/A$1.12B$20.65M0.004
KMTS
Kestra Medical Technologies
0.6227 of 5 stars
$22.68
+3.9%
$27.33
+20.5%
N/A$1.12B$59.81M0.00300Positive News
Analyst Upgrade
High Trading Volume
ESTA
Establishment Labs
2.1709 of 5 stars
$36.84
-1.7%
$56.50
+53.4%
-2.0%$1.09B$166.02M-12.081,018Positive News
Analyst Upgrade
MDXG
MiMedx Group
3.4151 of 5 stars
$6.97
+0.4%
$12.00
+72.2%
+17.3%$1.03B$348.88M33.19870Positive News
PLSE
Pulse Biosciences
4.1764 of 5 stars
$15.74
+8.4%
$22.00
+39.8%
-1.7%$977.14M$700K-14.99140Positive News
Insider Trade
Gap Up
High Trading Volume
INMD
InMode
2.6214 of 5 stars
$14.86
+0.2%
$18.04
+21.4%
-13.8%$937.39M$394.82M6.02480Positive News
IRMD
iRadimed
4.7813 of 5 stars
$71.61
+0.5%
$72.00
+0.5%
+47.4%$906.20M$73.24M44.20110Positive News
EMBC
Embecta
4.4463 of 5 stars
$15.08
+0.5%
$19.00
+26.0%
-6.5%$877.86M$1.12B10.552,100Positive News

Related Companies and Tools


This page (NASDAQ:NPCE) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners